MIAMI BEACH -- Emerging data have helped optimize the use of CDK4/6 inhibitors in metastatic hormone receptor (HR)-positive breast cancer, and the focus has turned to overcoming resistance, a breast ...
As clinicians celebrated results of the PALOMA-2 study at ASCO Annual Meeting in 2016, Gabe S. Sonke, MD, PhD, had a question ...
Kate Jeffers, PharmD: The CDK4/6 class works at a very particular place in the cell cycle, really adding additional benefit to your aromatase inhibitor therapy. You do definitely see increases in ...
Sara M. Tolaney, MD, MPH: Given the data that are available for the use of CDK4 and CDK6 inhibitors in metastatic hormone receptor—positive disease, I think the class of agents is really something ...
A real-world analysis shows "meaningful" overall survival benefits when a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor is added to endocrine therapy for older ...
In a phase III trial presented at the American Society of Clinical Oncology annual meeting, researchers compared abemaciclib (Verzenio) plus fulvestrant (Faslodex) versus fulvestrant plus placebo in ...
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results